Difference between revisions of "Part:BBa K4165148"
Line 9: Line 9:
 
W-MINK is a peptide with amino acid sequence of DVWMINKKRK, it is designed to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. W-MINK can bind to PHF* in a mean that can disrupt the interface between each PHF* and consequently reduce the aggregates. Its IC<sub>50</sub> for inhibition of tau aggregates were 1.1 μM.
 
W-MINK is a peptide with amino acid sequence of DVWMINKKRK, it is designed to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. W-MINK can bind to PHF* in a mean that can disrupt the interface between each PHF* and consequently reduce the aggregates. Its IC<sub>50</sub> for inhibition of tau aggregates were 1.1 μM.
  
 +
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 +
<partinfo>BBa_K4165148 SequenceAndFeatures</partinfo>
  
 
===Dry Lab===
 
===Dry Lab===
Line 31: Line 33:
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/wmink-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/wmink-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
 
</html>
 
</html>
−
 
−
 
−
<!-- -->
 
−
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 
−
<partinfo>BBa_K4165148 SequenceAndFeatures</partinfo>
 
−
 
  
 
===References===
 
===References===

Revision as of 17:04, 10 October 2022


W-MINK Peptide

Tau binding peptide targeting the PHF seed of Tau

Usage and Biology

W-MINK is a peptide with amino acid sequence of DVWMINKKRK, it is designed to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. W-MINK can bind to PHF* in a mean that can disrupt the interface between each PHF* and consequently reduce the aggregates. Its IC50 for inhibition of tau aggregates were 1.1 μM.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

W-MINK is modeled by AlphaFold2, Apptest, ITASSER and RosettaFold, best model obtained from AlphaFold2 



                            Figure 1.: Predicted 3D structure of Synthetic peptide W-MINK.


Table 1: Quality assessment parameters of W-MINK model.

References

1. Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., ... & Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. Nature chemistry, 10(2), 170-176.